APA (7th ed.) Citation

Ghazi, N. G., Krik, T. Q., Knape, R. M., Tiedeman, J. S., & Conway, B. P. (2010). Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?

Chicago Style (17th ed.) Citation

Ghazi, Nicola G., Tyler Q. Krik, Robert M. Knape, James S. Tiedeman, and Brian P. Conway. Is Monthly Retreatment with Intravitreal Bevacizumab (Avastin®) Necessary in Neovascular Age-related Macular Degeneration? 2010.

MLA (9th ed.) Citation

Ghazi, Nicola G., et al. Is Monthly Retreatment with Intravitreal Bevacizumab (Avastin®) Necessary in Neovascular Age-related Macular Degeneration? 2010.